This week, the Supreme Court of the United States heard oral arguments in Oil States Energy Services, LLC v Greene’s Energy Group, LLC, a case that asks the court to decide whether inter partes review (IPR) is constitutional.
This week, the Supreme Court of the United States heard oral arguments in Oil States Energy Services, LLC v Greene’s Energy Group, LLC, a case that asks the court to decide whether inter partes review (IPR), a proceeding before the US Patent Trial and Appeal Board that provides for the review of 1 or more claims of a patent, is constitutional.
While the case in question arises from a dispute over a patent held by an oilfield service company on equipment used in hydraulic fracturing, the court’s decision will have far-reaching implications for biosimilar stakeholders; the IPR process is regularly used by biosimilar developers to challenge patents for reference biologics, especially such blockbuster drugs as Rituxan (rituximab) and Herceptin (trastuzumab).
Counsel for Oil States, Allyson Ho, argued that patents can only be revoked by a federal court decision, and that IPR proceedings, which were established by Congress as part of the America Invents Act as a means to address patent reviews, violate an entity’s constitutional right to have challenges heard before a federal jury.
Arguing for Greene’s Energy Group, Christopher Kise argued that IPRs simply reexamine whether a patent should have been issued initially, and that IPRs do not involve the exercise of judicial power.
Big Molecule Watch reported that the outcome of the case is difficult to predict (some justices asked numerous questions while others asked none at all), and suggested that Justice Kennedy’s vote in the matter may be significant to the eventual decision.
Biosimilars stakeholders will be watching the case closely in the coming days; in a recent interview, attorney Robert Cerwinski told The Center for Biosimilars® that “IPRs have been one of the main tools in the tool kit of biosimilar applicants to try to clear a path for biosimilars to market.” He added, “The upshot is, if in fact the law that created IPRs is governed to be unconstitutional, Congress is going to have to take another shot at either modifying or redoing the statute that created IPRs. So, the potential impact on biosimilar applicants from having the IPR scheme eliminated entirely will be quite significant…there is a risk that the IPR world as we know it could change in the near term.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.